Skip to content

Efficacy and safety of autologous hyperleukocyte-polyplatelet plasma (L-PRP) therapy group compared to standard treatment group

Efficacy and safety of a randomized, parallel-group study of autologous hyperleukocyte-polyplatelet plasma therapy (L-PRP) versus standard therapy in tendon attachment disorders and ligament injuries.

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030250091
Enrollment
40
Registered
2025-05-08
Start date
2025-05-22
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tendon attachment disorders, ligament injuries Tendon attachment disorders, ligament injuries

Interventions

Approximately 30 ml of blood is collected from the patient, transferred to a special separation and extraction kit (GPS III), and centrifuged. 2 buoys of the GPS III are suspended to the appropriate p
L-PRP

Sponsors

Funasaki Hiroki
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with tendon attachment disorders (tendonitis or tendinopathy of Achilles tendon, patellar tendon, etc., and medial epicondylitis of humerus, lateral epicondylitis of humerus, etc.), ligament injuries (ligament injuries around elbow joint and knee joint, etc.) Patients who have obtained written consent from the patient Patients who do not have bacterial infections. Patients must be at least 20 years of age and of any gender.

Exclusion criteria

Exclusion criteria: Patients with systemic or local bacterial infections Patients whose systemic condition may be affected by infections caused by this therapy. Patients who have a fever of 37temperature or higher without antipyretics or analgesics. Patients with open wounds Patients undergoing oral therapy

Design outcomes

Primary

MeasureTime frame
Change in VAS before (baseline) and after 20 weeks of treatment intervention (VAS value after 20 weeks of intervention minus VAS value at baseline)

Secondary

MeasureTime frame
Physical findings (tenderness in the affected area, pain during stretching, pain during stress) Return-to-Sport Scale(J Scale)

Countries

Japan

Contacts

Public ContactTanaka Kouta

Jikei University Hospital

honeybee24k@yahoo.co.jp+81-3-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026